Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery
Thursday, October 03, 2024Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH a pioneering company known for its breakthroughs in biosensor development which is based in Munich Germany This acquisition strengthens Brukers biophysical portfolio
Abzena Expands Partnership with ProteoNic to Include 2G UNic® Technology as Standard Offering for All Customers
Thursday, October 03, 2024ProteoNic a leader in advanced protein expression technology is pleased to announce an expanded partnership with Abzena the leading endtoend integrated CDMO for complex biologics and bioconjugates Following the successful launch of AbZelectPRO
Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease
Thursday, October 03, 2024H Lundbeck AS Lundbeck today announced taking one further step in developing treatments for indications in the neuroimmunology and neuroinflammatory space with the initiation of the first clinical trial of its CDL blocker Lu AG in patients
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
Thursday, October 03, 2024Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd and mAbxience a Fresenius Kabi majorityowned group with partial ownership from Insud Pharma today announced a new global licensing agreement for the developmen...
Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities
Tuesday, October 01, 2024Scorpius Holdings Inc an integrated contract development and manufacturing organization CDMO announced it has signed a contract to provide bioanalytical services for a publicly traded clinicalstage immunooncology company
Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers
Tuesday, October 01, 2024Tessellate BIO a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches announces a collaboration with CMRI a leading Australian pediatric medical research institute and Omico an organization uniting over worldc...
Abzena Expands Partnership with ProteoNic to Include 2G UNic® Technology as Standard Offering for All Customers
Tuesday, October 01, 2024ProteoNic a leader in advanced protein expression technology is pleased to announce an expanded partnership with Abzena the leading endtoend integrated CDMO for complex biologics and bioconjugates Following the successful launch of AbZelectPRO
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
Tuesday, October 01, 2024Cybin Inca clinicalstage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative nextgeneration treatment options today announced the appointment of senior clinical team leaders Dr Mirza Ra...
AzurBio Pharma Launches to Fast-Track European Market Entry for Biopharma Companies with Breakthrough Treatments
Tuesday, October 01, 2024AzurBio Pharma specializing in bringing innovative pharmaceutical products to European markets and focusing on rare and serious diseases with unmet medical needs is announcing its official launch AzurBio Pharma is headquartered in Paris with a presen...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
Saturday, September 28, 2024Regeneron Pharmaceuticals Inc NASDAQ REGN and Sanofi today announced that the US Food and Drug Administration FDA has approved Dupixent dupilumab as an addon maintenance treatment of adults with inadequately controlled chronic obstructive
